Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection

Vaccine

Volumn 28, Issue 2, 2009, Pages 430-436

  Sellhorn, George ^a   Caldwell, Zachary ^a   Mineart, Christine ^a   Stamatatos, Leonidas ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Envelope; Expression; HIV

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL STRAIN HEK293; COMPARATIVE STUDY; CONTROLLED STUDY; DNA TRANSFECTION; GENE INSERTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HUMANS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 70649096029     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.028     Document Type: Article

References (60)

1. Walker B.D., and Burton D.R. Toward an AIDS vaccine. Science 320 May (5877) (2008) 760-764
2. Hu S.L., and Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr HIV Res 5 November (6) (2007) 507-513
3. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80 March (5) (2006) 2515-2528
4. Phogat S., Wyatt R.T., and Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 262 July (1) (2007) 26-43
5. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 77 January (1) (2003) 353-365
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 December (23) (2004) 13232-13252
7. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 June (5628) (2003) 2065-2071
8. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 February (2) (2005) 163-173
9. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67 November (11) (1993) 6642-6647
10. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78 October (19) (2004) 10724-10737
11. Roben P., Moore J.P., Thali M., Sodroski J., Barbas III C.F., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68 August (8) (1994) 4821-4828
12. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75 June (12) (2001) 5526-5540
13. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79 July (14) (2005) 8812-8827
14. Derby N.R., Gray S., Wayner E., Campogan D., Vlahogiannis G., Kraft Z., et al. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology 366 September (2) (2007) 433-445
15. Dey A.K., David K.B., Klasse P.J., and Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360 March (1) (2007) 199-208
16. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75 January (2) (2001) 645-653
17. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 January (1) (2005) 33-46
18. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., and Liao H.X. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 21 January (1) (2005) 58-67
19. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., and Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80 February (3) (2006) 1414-1426
20. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14 January (2) (1998) 151-155
21. Haigwood N.L., Shuster J.R., Moore G.K., Lee H., Skiles P.V., Higgins K.W., et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses 6 July (7) (1990) 855-869
22. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360 April (2) (2007) 329-340
23. Burke B., Derby N.R., Kraft Z., Saunders C.J., Dai C., Llewellyn N., et al. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies. Virology 355 November (2) (2006) 138-151
24. Doria-Rose N.A., Learn G.H., Rodrigo A.G., Nickle D.C., Li F., Mahalanabis M., et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79 September (17) (2005) 11214-11224
25. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79 January (2) (2005) 1154-1163
26. Richardson Jr. T.M., Stryjewski B.L., Broder C.C., Hoxie J.A., Mascola J.R., Earl P.L., et al. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 70 February (2) (1996) 753-762
27. Xu J., Ren L., Huang X., Qiu C., Liu Y., and Shao Y. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS 20 November (18) (2006) 2293-2303
28. Yang X., Wyatt R., and Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75 February (3) (2001) 1165-1171
29. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci USA 104 June (24) (2007) 10193-10198
30. Meissner P., Pick H., Kulangara A., Chatellard P., Friedrich K., and Wurm F.M. Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells. Biotechnol Bioeng 75 October (2) (2001) 197-203
31. Baldi L., Hacker D.L., Adam M., and Wurm F.M. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29 May (5) (2007) 677-684
32. Backliwal G., Hildinger M., Hasija V., and Wurm F.M. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 99 February (3) (2008) 721-727
33. Carpentier E., Paris S., Kamen A.A., and Durocher Y. Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. J Biotechnol 128 February (2) (2007) 268-280
34. Hwang S.J., Kim S.H., Kim H.Z., Steinmetz M.O., Koh G.Y., and Lee G.M. High-level expression and purification of a designed angiopoietin-1 chimeric protein. COMP-Ang1, produced in Chinese hamster ovary cells. Protein J 27 August (5) (2008) 319-326
35. Liu C., Dalby B., Chen W., Kilzer J.M., and Chiou H.C. Transient transfection factors for high-level recombinant protein production in suspension cultured mammalian cells. Mol Biotechnol 39 June (2) (2008) 141-153
36. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22 November (11) (2004) 1393-1398
37. Geisse S., and Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production. J Struct Funct Genomics 6 2-3 (2005) 165-170
38. Parham J.H., Kost T., and Hutchins J.T. Effects of pCIneo and pCEP4 expression vectors on transient and stable protein production in human and simian cells lines. Cytotechnology 35 (2001) 181-187
39. Schlaeger E.J., Kitas E.A., and Dorn A. SEAP expression in transiently transfected mammalian cells grown in serum-free suspension culture. Cytotechnology 42 May (1) (2003) 47-55
40. Sun X., Goh P.E., Wong K.T., Mori T., and Yap M.G. Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension. Biotechnol Lett 28 June (11) (2006) 843-848
41. Blish C.A., Nedellec R., Mandaliya K., Mosier D.E., and Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21 March (6) (2007) 693-702
42. Cheng-Mayer C., Weiss C., Seto D., and Levy J.A. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci USA 86 November (21) (1989) 8575-8579
43. Durocher Y., Perret S., and Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30 January (2) (2002) E9
44. Yates J., Warren N., Reisman D., and Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81 June (12) (1984) 3806-3810
45. Yates J.L., Warren N., and Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 February-March (6005) (1985) 812-815
46. Muller N., Girard P., Hacker D.L., Jordan M., and Wurm F.M. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol Bioeng 89 February (4) (2005) 400-406
47. Backliwal G., Hildinger M., Chenuet S., Wulhfard S., De Jesus M., and Wurm F.M. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 36 September (15) (2008) e96
48. Blay W.M., Kasprzyk T., Misher L., Richardson B.A., and Haigwood N.L. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J Virol 81 December (23) (2007) 13037-13049
49. Kraft Z., Derby N.R., McCaffrey R.A., Niec R., Blay W.M., Haigwood N.L., et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 81 June (12) (2007) 6402-6411
50. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 January (2) (2009) 757-769
51. Kirschner M., Monrose V., Paluch M., Techodamrongsin N., Rethwilm A., and Moore J.P. The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 48 July (1) (2006) 61-68
52. Dey A.K., David K.B., Ray N., Ketas T.J., Klasse P.J., Doms R.W., et al. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 372 March (1) (2008) 187-200
53. Kumar S., Yan J., Muthumani K., Ramanathan M.P., Yoon H., Pavlakis G.N., et al. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. DNA Cell Biol 25 July (7) (2006) 383-392
54. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77 October (20) (2003) 11244-11259
55. Pham P.L., Kamen A., and Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol 34 October (2) (2006) 225-237
56. Sun X., Hia H.C., Goh P.E., and Yap M.G. High-density transient gene expression in suspension-adapted 293 EBNA1 cells. Biotechnol Bioeng 99 January (1) (2008) 108-116
57. Grillberger L., Kreil T.R., Nasr S., and Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4 February (2) (2009) 186-201
58. Loignon M., Perret S., Kelly J., Boulais D., Cass B., Bisson L., et al. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol 8 (2008) 65
59. Zhang J., Liu X., Bell A., To R., Baral T.N., Azizi A., et al. Transient expression and purification of chimeric heavy chain antibodies. Protein Expr Purif 65 May (1) (2009) 77-82
60. Zhang J., MacKenzie R., and Durocher Y. Production of chimeric heavy-chain antibodies. Methods Mol Biol 525 (2009) 323-336 xv